Form 4: Director Ilan Oren Reports Roivant Sciences Stock Activity

Director Ilan Oren acquired 896 common shares of Roivant Sciences Ltd. as part of director compensation, with a portion withheld for taxes.

Summary

• Director Ilan Oren received 896 common shares as part of the company's Non-Employee Director Compensation Plan.
• The shares were fully vested upon the grant date of April 17, 2026.
• A total of 95 shares were withheld by the company at a price of $29.83 per share to satisfy tax withholding obligations.
• Following these transactions, the director's total beneficial ownership stands at 120,229 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Director maintains a significant equity stake of 120,229 shares, aligning interests with shareholders.

Negatives

• None identified; this is a routine compensation-related transaction.

Risks

• None identified; this is a standard regulatory disclosure of director equity compensation.

Future Outlook

Not applicable; this is a retrospective disclosure of an equity grant.

Industry Context

StockSavvy.ai notes that routine equity grants to non-employee directors are standard corporate governance practices in the biotechnology sector, intended to incentivize long-term board oversight.

Comparison to Industry Standards

• The use of net settlement for tax obligations is a standard practice among publicly traded companies to simplify tax compliance for directors.
• The grant of equity as part of a non-employee director compensation plan is consistent with market practices for mid-to-large cap biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the transaction represents standard director compensation.

Next Steps

• No future actions required by the reporting person beyond continued compliance with Section 16 reporting requirements.

Key Dates

Keywords

Roivant Sciences, ROIV, Form 4, Insider Trading, Director Compensation, Equity Ownership